Neuroscience
A press release from the NIH:
Tuesday, October 11, 2005
CONTACT: Margo Warren 301-496-5751
Science Reporters Briefing: New Advances in Parkinson’s Research and Treatment
What:
The National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Parkinson’s community is bringing together a panel of leading physicians, scientists, and caregivers to provide an overview of the newest advances in Parkinson’s disease. Researchers will discuss genetic aspects of the disease, new approaches to therapeutics, and environmental and other factors that may impact onset of Parkinson’s. Panelists will discuss their work and respond to questions from the audience.
Why:
After Alzheimer’s disease, Parkinson’s is the most common neurodegenerative disorder. There are an estimated 6.3 million people worldwide suffering from Parkinson's disease. Because of the aging world population, and given that the number of older Americans will more than double to 70 million by 2030, now is the time to begin gaining a better understanding of diseases, such as Parkinson’s, that have a significant impact on older adults.
Who:
Experts in Parkinson’s disease will make brief remarks. A session for questions and answers will follow each speaker.
- Story Landis, Ph.D., Director, NINDS
- J. Timothy Greenamyre, M.D., Ph.D., University of Pittsburgh Medical Center, Environmental Influences and Parkinson’s Disease (PD)
- Robert L. Nussbaum, M.D., National Human Genome Research Institute, Genetics of PD
- Peter T. Lansbury, Jr., Ph.D., Brigham and Women’s Hospital, Drug Discovery for PD
- Clive Svendsen, M.D., University of Wisconsin-Madison, Future Therapeutic Approaches
- Monique Giroux, M.D., The Cleveland Clinic Foundation, Caring for Patients with PD Across the Clinical Spectrum
- Morton Kondracke, Author of Saving Milly, Caregiver’s Perspective
When:
Thursday, October 20, 2005, 10:00 a.m. ET
Where:
The Dana Center 900 15th St, NW, Washington, DC
-
Anthony H. Risser | neuroscience | neuropsychology | brain
parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Parkinson Disease Update Live On C-span Today
The Parkinson Disease event presented by the NIH, which I noted here earlier [BrainBlog post on 11 October 2005] was broadcast live today on C-SPAN: Advances in Parkinson's Disease. Check the C-SPAN website for any reairing dates and times. - Anthony...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Awareness Month: Parkinson’s Disease
April is National Parkinson's Awareness Month. Parkinson’s disease, a degenerative disorder of the central nervous system, has no known cause in most cases. Medically, Parkinson’s has been traced to the death of dopamine-generating cells in the...
Neuroscience
Upcoming Event: Washington, D.C., 20 October 2005
A press release from the NIH:
Tuesday, October 11, 2005
CONTACT: Margo Warren 301-496-5751
Science Reporters Briefing: New Advances in Parkinson’s Research and Treatment
What:
The National Institute of Neurological Disorders and Stroke (NINDS) in partnership with the Parkinson’s community is bringing together a panel of leading physicians, scientists, and caregivers to provide an overview of the newest advances in Parkinson’s disease. Researchers will discuss genetic aspects of the disease, new approaches to therapeutics, and environmental and other factors that may impact onset of Parkinson’s. Panelists will discuss their work and respond to questions from the audience.
Why:
After Alzheimer’s disease, Parkinson’s is the most common neurodegenerative disorder. There are an estimated 6.3 million people worldwide suffering from Parkinson's disease. Because of the aging world population, and given that the number of older Americans will more than double to 70 million by 2030, now is the time to begin gaining a better understanding of diseases, such as Parkinson’s, that have a significant impact on older adults.
Who:
Experts in Parkinson’s disease will make brief remarks. A session for questions and answers will follow each speaker.
- Story Landis, Ph.D., Director, NINDS
- J. Timothy Greenamyre, M.D., Ph.D., University of Pittsburgh Medical Center, Environmental Influences and Parkinson’s Disease (PD)
- Robert L. Nussbaum, M.D., National Human Genome Research Institute, Genetics of PD
- Peter T. Lansbury, Jr., Ph.D., Brigham and Women’s Hospital, Drug Discovery for PD
- Clive Svendsen, M.D., University of Wisconsin-Madison, Future Therapeutic Approaches
- Monique Giroux, M.D., The Cleveland Clinic Foundation, Caring for Patients with PD Across the Clinical Spectrum
- Morton Kondracke, Author of Saving Milly, Caregiver’s Perspective
When:
Thursday, October 20, 2005, 10:00 a.m. ET
Where:
The Dana Center 900 15th St, NW, Washington, DC
-
Anthony H. Risser | neuroscience | neuropsychology | brain
parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Parkinson Disease Update Live On C-span Today
The Parkinson Disease event presented by the NIH, which I noted here earlier [BrainBlog post on 11 October 2005] was broadcast live today on C-SPAN: Advances in Parkinson's Disease. Check the C-SPAN website for any reairing dates and times. - Anthony...
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Awareness Month: Parkinson’s Disease
April is National Parkinson's Awareness Month. Parkinson’s disease, a degenerative disorder of the central nervous system, has no known cause in most cases. Medically, Parkinson’s has been traced to the death of dopamine-generating cells in the...